NCT04390009 (EPSMS) is a EARLY_PHASE1 clinical trial of Entire-body PET-CT scans in Multiple Sclerosis, sponsored by Brain Health Alliance.

Who is sponsoring NCT04390009?

NCT04390009 is sponsored by Brain Health Alliance.

What drugs are being tested in NCT04390009?

Interventions in NCT04390009: Entire-body PET-CT scans, Amyvid radiopharmaceutical.

What condition does NCT04390009 study?

NCT04390009 studies Multiple Sclerosis.

Is NCT04390009 still recruiting?

NCT04390009 is currently recruiting now. Last updated 7 January 2025.

Last reviewed 2025-01-07 · How we verify

NCT04390009: EPSMS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Entire-body PET Scans for Multiple Sclerosis

Recruiting now EARLY_PHASE1 Last updated 7 January 2025

What this trial tests

EARLY_PHASE1 trial testing Entire-body PET-CT scans in Multiple Sclerosis in 20 participants. Currently enrolling.

Timeline

30 September 2024

Primary endpoint
30 September 2025

30 December 2025

Quick facts

Lead sponsor	Brain Health Alliance
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	20
Start date	30 September 2024
Primary completion	30 September 2025
Estimated completion	30 December 2025
Sites	1 location across United States

Drugs / interventions tested

Entire-body PET-CT scans
Amyvid radiopharmaceutical — full drug profile →

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

Brain Health Alliance — full company profile →

Who can join

Adults 25 to 55, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04390009 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brain Health Alliance
Last refreshed: 7 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04390009.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing